Scotland Highlights New Partnerships and Cutting-Edge Drug Discover...( Recent stem cell advances and Sir Phi...)

Recent stem cell advances and Sir Philip Cohen's groundbreaking research into new drug targets showcase Scotland's life sciences innovation at BIO 2009

ATLANTA, May 18 /PRNewswire/ -- At this year's BIO International Convention, May 18-21 in Atlanta, Scotland will showcase the commercial success of its research collaborations with global pharmaceutical and biotech companies, as well as major scientific advancements in stem cells, drug discovery, translational medicine, medical technology and preclinical and clinical research.

With representation from more than 30 companies and organizations, including Scottish Enterprise, Scottish Development International and TalentScotland, the Scottish Pavilion at BIO will display exceptional collaboration among industry, academia and government in its life sciences sector. Scotland's internationally-renowned universities, rich talent base and unprecedented scientific legacy make it a natural home to one of the largest and fastest growing life science clusters in Europe, with more than 620 life science organizations and over 31,000 employees.

At this year's conference, Scotland will present a panel on 'The Ubiquitin Story,' a look at an exciting new research area in which Scotland has invested heavily through the $15 million Scottish Institute for Cell Signaling (SCILLS) and the $14 million ITI Life Sciences Ubiquitin Proteasome System (UPS) drug discovery program. Participating in the panel session will be University of Dundee's Sir Philip Cohen, world-renowned biochemist and newly inducted member of the U.S. National Academy of Science, whose leadership developing protein kinases as key drug targets has paved the way for several of the leading oncology therapies available to patients today. Professor Mike Tyers, Director of the Scottish Universities Life Sciences Alliance (SULSA), along with industry experts from around the world, will offer scienti
'/>"/>